Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Activated macrophages contribute to the pathogenesis of vascular disease. Vein graft failure is a major clinical problem with limited therapeutic options. PCSK9 (proprotein convertase subtilisin/kexin 9) increases low-density lipoprotein (LDL)-cholesterol levels via LDL receptor (LDLR) degradation. The role of PCSK9 in macrophage activation and vein graft failure is largely unknown, especially through LDLR-independent mechanisms. This study aimed to explore a novel mechanism of macrophage activation and vein graft disease induced by circulating PCSK9 in an LDLR-independent fashion. Methods: We used Ldlr -/- mice to examine the LDLR-independent roles of circulating PCSK9 in experimental vein grafts. Adeno-associated virus (AAV) vector encoding a gain-of-function mutant of PCSK9 (rAAV8/D377Y-mPCSK9) induced hepatic PCSK9 overproduction. To explore novel inflammatory targets of PCSK9, we used systems biology in Ldlr -/- mouse macrophages. Results: In Ldlr -/- mice, AAV-PCSK9 increased circulating PCSK9, but did not change serum cholesterol and triglyceride levels. AAV-PCSK9 promoted vein graft lesion development when compared with control AAV. In vivo molecular imaging revealed that AAV-PCSK9 increased macrophage accumulation and matrix metalloproteinase activity associated with decreased fibrillar collagen, a molecular determinant of atherosclerotic plaque stability. AAV-PCSK9 induced mRNA expression of the pro-inflammatory mediators IL-1β (interleukin-1 beta), TNFα (tumor necrosis factor alpha), and MCP-1 (monocyte chemoattractant protein-1) in peritoneal macrophages underpinned by an in vitro analysis of Ldlr -/- mouse macrophages stimulated with endotoxin-free recombinant PCSK9. A combination of unbiased global transcriptomics and new network-based hyperedge entanglement prediction analysis identified the NF-κB (nuclear factor-kappa B) signaling molecules, lectin-like oxidized LOX-1 (LDL receptor-1), and SDC4 (syndecan-4) as potential PCSK9 targets mediating pro-inflammatory responses in macrophages. Conclusions: Circulating PCSK9 induces macrophage activation and vein graft lesion development via LDLR-independent mechanisms. PCSK9 may be a potential target for pharmacologic treatment for this unmet medical need.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Libby, P. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1216063 · Cited by 1,262
Self-citationBonaca, M. P., Nault, P., Giugliano, R. P., Keech, A. C., Pineda, A. L., Kanevsky, E., Kuder, J., Murphy, S. A., Jukema, J. W., Lewis, B. S., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032235 · Cited by 766
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701488 · Cited by 624 · cited 1×
“12,13 PCSK9 monoclonal antibodies reduce the risk of major cardiovascular events 14,15 and adverse limb events which is not possible by statin treatment alone.”
Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis
Yahagi, K., Kolodgie, F. D., Otsuka, F., Finn, A. V., Davis, H. R., Joner, M., & Virmani, R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.164 · Cited by 548 · cited 1×
“The key findings include: (1) AAV-PCSK9 did not change lipid profile but promoted vein graft lesion development in Ldlr-/- mice, suggesting LDLR-independent mechanisms; (2) AAV-PCSK9 increased macrophage accumulation and decreased fibrillar collagen in vein graft lesions; (3) PCSK9 induced macrophage activation in Ldl…”
Cited by
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease
Han, D., Zhou, T., Li, L., Ma, Y., Chen, S., Yang, C., Ma, N., Song, M., Zhang, S., Wu, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065213 · Cited by 38
Jin, P., Ma, J., Wu, P., Yan, R., Bian, Y., Jia, S., Zheng, Q., & Ma, X. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117031 · Cited by 9
Metadata
- Authors
- Katsuki, S., K. Jha, P., Lupieri, A., Nakano, T., Passos, L. S. A., Rogers, M. A., Becker-Greene, D., Le, T.-D., Decano, J. L., Ho Lee, L., Guimaraes, G. C., Abdelhamid, I., Halu, A., Muscoloni, A., V. Cannistraci, C., Higashi, H., Zhang, H., Vromman, A., Libby, P., Keith Ozaki, C., Sharma, A., Singh, S. A., Aikawa, E., & Aikawa, M.
- Venue
- Circulation Research
- Published
- 2022-11-11
- Volume
- 131
- Issue
- 11
- Pages
- 873-889
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W4306867657
- Cited by
- 76
- References
- 18
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms. https://app.cochat.ai/papers/10.1161/circresaha.121.320056
- The paper
- Katsuki, S., K. Jha, P., Lupieri, A., Nakano, T., Passos, L. S. A., Rogers, M. A., Becker-Greene, D., Le, T.-D., Decano, J. L., Ho Lee, L., Guimaraes, G. C., Abdelhamid, I., Halu, A., Muscoloni, A., V. Cannistraci, C., Higashi, H., Zhang, H., Vromman, A., Libby, P., . . . Aikawa, M. (2022). Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms. Circulation Research. https://doi.org/10.1161/circresaha.121.320056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.